

RealRate

PHARMACEUTICAL 2020



ANAPTYSBIO INC Rank 25 of 358







PHARMACEUTICAL 2020



RealRate

ANAPTYSBIO INC Rank 25 of 358

The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of ANAPTYSBIO INC is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 259%, being 222% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	377,733
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,535
Liabilities, Non-Current	0
Other Assets	55,846
Other Compr. Net Income	561
Other Expenses	-152
Other Liabilities	0
Other Net Income	9,944
Other Revenues	8,000
Property and Equipment	1,618
Research and Development	99,338
Selling, General and Administrative Expense	16,094

Output Variable	Value in 1000 USD
Assets	435,197
Liabilities	29,535
Expenses	115,280
Revenues	8,000
Stockholders Equity	405,662
Net Income	-97,336
Comprehensive Net Income	-97,056
Economic Capital Ratio	259%

